A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.

摘要: Rationale: Roflumilast is a therapeutic agent in the treatment of chronic obstructive pulmonary disease (COPD). It has antiinflammatory effects; however, it not known whether can affect biologic pathway implicated COPD pathogenesis and progression. The self-propagating acetyl-proline-glycine-proline (AcPGP) novel means neutrophilic inflammation that pathologic development COPD. AcPGP produced by extracellular matrix collagen breakdown with prolyl endopeptidase leukotriene A4 hydrolase serving as enzymes responsible for its production degradation, respectively.Objectives: We hypothesized roflumilast would decrease AcPGP, halting feed-forward cycle inflammation.Methods: conducted single-center, placebo-controlled, randomized study investigating 12 weeks added to current therapy moderate-to-severe bronchitis. Subjects underwent sputum blood analyses, function testing, exercise t...